|
|
Article: Stiefel Laboratories Receives FDA Approval of Olux-E (Clobetasol Propionate) Foam, 0.05% for Treatment of Psoriasis and Eczema.
- Article from:
- Business Wire
- Article date:
- January 23, 2007
CopyrightCOPYRIGHT 2007 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
-- Company's Second Product in Emollient-Based Foam Delivery Vehicle --
CORAL GABLES, Fla. -- Stiefel Laboratories, Inc., the world's largest independent pharmaceutical company specializing in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved Olux-E[TM] (clobetasol propionate) Foam, 0.05%. Olux-E is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, also known as psoriasis and eczema, in patients 12 years of age or older. In clinical studies, Olux-E was shown to safely and effectively reduce the symptoms associated with psoriasis and eczema. Olux-E is expected ...
Related newspaper, magazine, and journal articles:
|
|
Article: STIEFEL LABORATORIES APPOINTS FIRST CHIEF ...
AsiaPulse News;
April 8, 2008 ;
700+ words
... ... infections. About Stiefel Laboratories, Inc. Founded in 1847, Stiefel Laboratories (a privately ... R) Cream; Olux(R) (clobetasol ... Olux(R) / Olux-E(TM) COMPLETE ... around the world. Stiefel Laboratories supplements its ...
|
|